Chuck Hadley began his venture capital career with Hillman Medical Ventures, an early stage medical technology fund, which he co-founded in 1988. He led that firm's medical device sector investing. He was the founding investor in Ultracision (acquired by Johnson & Johnson) and led the firm's investments in several other device and diagnostics companies, including Cytyc (NASDAQ:CYTC), Dynamic Digital Displays (acquired by Picker International), Fiberoptic Sensor Technologies (acquired by C.R. Bard) and Endius (acquired by Zimmer). In 1997, Chuck founded Rock Hill Ventures. There he founded several medical technology companies, including Talaria Therapeutics (acquired by Esperion Therapeutics/Pfizer - NYSE:PFE), Transport Pharmaceuticals, and Replication Medical, and he led the first round of investment in Proxima Therapeutics (acquired by Cytyc). Chuck is currently a board member of Bioconnect Systems, Fluidnet and serves as Chairman of Transport Pharmaceuticals and Chairman of Replication Medical.

Chuck was a member of the Board of Directors of the Greater Philadelphia Venture Group from 1991 to 1995 where he served as President in 1993-1994 and Chairman in 1994-1995. He has also served on the investment advisory board of the Ben Franklin Technology Center of Southeastern Pennsylvania.

From 1986 to 1987, Chuck worked in Ghana, West Africa for Technoserve, a non-government agency focused on helping rural, low income people start and manage agricultural businesses. He worked for Imatron from 1983 to 1986 where he served as Vice President and General Counsel. He led the company's regulatory efforts, and helped raise several rounds of private financing and complete an initial public offering.

Chuck is a Phi Beta Kappa graduate of the George Washington University and received his J.D. and M.B.A. degrees from Stanford University in 1983.